The field of immunotherapy is a work in progress and researchers are now expanding the use of this treatment and doing a better job of identifying the patients that will benefit the most from it.
During the latest Managed Care Cast, Patricia Salber, MD, MBA, of The Doctor Weighs In, interviews Harold J. Burstein, MD, PhD, an oncologist with the Dana-Farber Cancer Institute, about immunotherapy 2.0, which was named the advance of the year by the American Society of Clinical Oncology (ASCO). This is the second year in a row that ASCO named immunotherapy the advance of the year; however, immunotherapy 2.0 acknowledges the expanding use of immunotherapy.
According to Burstein, the report recognizes that immunotherapy is a work in progress and that researchers are now doing a better job of identifying patients and tumor subsets that will benefit the most from this therapy. During the interview, Burstein and Salber also discuss toxicities related to immunotherapy and paying for the treatment.
Listen below or through one of these podcast services:
iTunes: http://apple.co/2eYWTss
TuneIn: http://bit.ly/2gv7iwj
Stitcher: http://bit.ly/2gCqtFg
Uniting to Support Patients With Cancer Beyond Treatment
November 17th 2024Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.
Read More
Bridging Cancer Care Gaps and Overcoming Medical Mistrust
November 13th 2024In this clip from our interview with Oscar B. Lahoud, MD, cochair of our Institute for Value-Based Medicine® evening hosted with NYU Langone Health, he addressed medical mistrust in underrepresented communities.
Read More
How English- and Spanish-Preferring Patients With Cancer Decide on Emergency Care
November 13th 2024Care delivery innovations to help patients with cancer avoid emergency department visits are underused. The authors interviewed English- and Spanish-preferring patients at 2 diverse health systems to understand why.
Read More